Recent 8-K filings for TTRX
Highest-materiality recent filing
Turn Therapeutics Announces Final Stage 2 Design and Expansion of GX-03 Phase 2 Trial
- Interim analysis of GX-03 Phase 2 trial in atopic dermatitis showed Week 4 vIGA-AD Success 71.4% vs 33.3% vehicle in EASI 1.1-7.0 subgroup.
- Final Stage 2 design will enroll 120-135 patients across full EASI spectrum (≥1.1) using Hochberg multiple testing procedure for four endpoints.
-
Turn Therapeutics (Nasdaq: TTRX) furnished an updated corporate/investor presentation dated October 6, 2026 under Item 7.01 (Regulation FD).
-
Turn Therapeutics to present at Stifel 2026 Virtual Immunology and Inflammation Forum
CEO Bradley Burnam and Dr. Stephen M. Hahn to present on September 23, 2026 at 1:30 PM ET.
-
Turn Therapeutics appoints former CDC Director Robert Redfield as Chief Scientific Officer
Robert R. Redfield, M.D., former CDC Director, named Chief Scientific Officer effective Sept 9, 2026.
-
Turn Therapeutics issues 579,664 shares to GEM on cashless warrant exercise
On Aug 13, 2026, GEM exercised warrant in full via cashless provision; company issued 579,664 common shares.
-
Turn Therapeutics raises $1.35M in private placement of 135,000 shares at $10.00/share
Sold 135,000 shares of common stock at $10.00 per share to accredited investors, including existing series and seed investors.
-
Turn Therapeutics Q2 net loss $5.85M; GX-03 Phase 2 interim data positive, expands study
Net loss $5.85M (-$0.20/share) vs $1.24M (-$0.05) in Q2 2025; cash $10.3M, runway into Q3 2027.
-
Turn Therapeutics releases updated investor presentation; no specific details provided
Filed under Item 7.01 Regulation FD; presentation dated July 28, 2026.
-
Turn Therapeutics Announces Final Stage 2 Design and Expansion of GX-03 Phase 2 Trial
Interim analysis of GX-03 Phase 2 trial in atopic dermatitis showed Week 4 vIGA-AD Success 71.4% vs 33.3% vehicle in EASI 1.1-7.0 subgroup.
-
Investor presentation dated June 3, 2026, released for the Jefferies Global Healthcare Conference.
-
Turn Therapeutics GX-03 Phase 2 interim: 92.6% EASI-50 at 4 weeks; no SAEs
92.6% of GX-03 subjects achieved EASI-50 at 4 weeks vs 65.2% vehicle; 70.4% achieved EASI-75.
-
Study in murine dermatitis model showed mean IGA score of 1.44 vs 3.00 for untreated controls (p=0.0003) after 7 days of GX-03.
-
Turn Therapeutics CEO to present at Jefferies Global Healthcare Conference June 4
Bradley Burnam, CEO, to present at Jefferies Global Healthcare Conference in New York City on June 4, 2026.
-
Turn Therapeutics appoints former FDA Commissioner Dr. Stephen Hahn as clinical and regulatory lead
Dr. Stephen M. Hahn, former FDA Commissioner, appointed to oversee clinical and regulatory strategy for GX-03.
-
Turn Therapeutics Q1 net loss $971K; Phase 2 AD trial on track, topline mid-2026
Cash and equivalents $11.2M as of March 31, 2026, up from $5.1M at Dec 31, 2025.
-
Turn Therapeutics reports FY2025 net loss of $3.2M; secures up to $25M venture debt
Cash and equivalents $5.08M as of Dec 31, 2025, excludes $7M initial tranche from Avenue Capital facility.
-
Turn Therapeutics secures up to $25M growth capital loan from Avenue Capital Group
Initial $7M tranche funded at closing; up to $18M additional available upon clinical and corporate milestones.
-
Turn Therapeutics appoints former CDC Director Dr. Robert Redfield as Senior Advisor for GX-03
Dr. Redfield appointed Senior Advisor of Health Policy and Regulatory Affairs, effective immediately.
-
Turn Therapeutics announces presentations at TD Cowen and Oppenheimer healthcare conferences
CEO Brad Burnam to present at 46th Annual TD Cowen Healthcare Conference in Boston on March 2, 2026.
-
Phase 2 trial of GX-03 for moderate-severe atopic dermatitis on track; interim and topline data expected first half of 2026.
-
Turn Therapeutics appoints Martin Dewhurst to its Board of Directors
Board expanded from 5 to 6 members; Dewhurst appointed as independent Class III director effective Jan 7, 2026.
-
Turn Therapeutics Q3 net loss $1.9M; enters global Medline PermaFusion deal
Net loss of $1.9M ($0.07/share) vs $0.67M loss in Q3 2024; G&A surged to $1.75M on listing costs.
-
GX-03 named one of five novel mechanisms in atopic dermatitis by Patient Care Online
GX-03 technology recognized by Patient Care Online alongside candidates from Amgen, Sanofi, Leo Pharma, Apogee, and Nektar.
-
Turn Therapeutics Appoints Andrew Scott as VP of Corporate Communications
Andrew Scott appointed VP of Corporate Communications effective November 4, 2025.
-
Turn Therapeutics enters global supply, development, and license agreement with Medline
Agreement covers development, manufacture, and commercialization of products using Turn's PermaFusion delivery platform.
-
Turn Therapeutics enters global supply and development pact with Medline for PermaFusion platform
Turn grants Medline exclusive worldwide license to use Turn's 510(k) clearance for wound-care field-of-use.
-
Phase 2 trial of GX-03 (topical IL-36/IL-31 inhibitor) for moderate-severe eczema: ~25% of targeted sample completed, no safety concerns; topline results expected in 2026.
-
Turn Therapeutics effects direct listing on Nasdaq; appoints two independent directors
SEC declared effective S-1 for direct listing of up to 17,868,760 shares of common stock on Nasdaq Global Market.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.55 · Most common event other_material